enGene (NASDAQ:ENGNW) Shares Down 14.4% – Should You Sell?

enGene Holdings Inc. (NASDAQ:ENGNW) shares traded down 14.4% on Monday . The company traded as low as $0.3390 and last traded at $0.2750. 300 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 17,162 shares. The stock had previously closed at $0.3213.

Key Stories Impacting enGene

Here are the key news stories impacting enGene this week:

• Positive Sentiment: No company-specific positive news was identified in the articles provided.
• Neutral Sentiment: Most headlines relate to broader engine and aerospace developments, including GE and CFM engine testing, repair-capacity investments, and airline engine deals, but they do not mention enGene Holdings or its products. Article Title
• Neutral Sentiment: Other items are general-interest articles about diesel engines, turbos, and V8 engines, which are unlikely to affect ENGNW’s stock. Article Title
• Negative Sentiment: With no meaningful operational or clinical updates tied to enGene Holdings, the stock’s decline may simply reflect thin trading and a lack of fresh company-specific buying interest rather than a direct negative headline. Article Title

enGene Stock Down 14.4%

The firm’s 50 day simple moving average is $0.26 and its 200-day simple moving average is $1.83.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.